NCT07044700View on ClinicalTrials.gov

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Not yet recruitingOBSERVATIONAL
Enrollment

5,000

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Heart Failure of Reduced Ejection Fraction (HFrEF)
Interventions
DRUG

Jardiance

Jardiance

DRUG

non-SGLT2 inhibitors

non-SGLT2 inhibitors

Trial Locations (1)

100037

Fuwai Hospital; National Center for Cardiovascular Diseases, Beijing

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY